MX348668B - Nanopartículas de oxaliplatin y método para prepararlas. - Google Patents

Nanopartículas de oxaliplatin y método para prepararlas.

Info

Publication number
MX348668B
MX348668B MX2012003393A MX2012003393A MX348668B MX 348668 B MX348668 B MX 348668B MX 2012003393 A MX2012003393 A MX 2012003393A MX 2012003393 A MX2012003393 A MX 2012003393A MX 348668 B MX348668 B MX 348668B
Authority
MX
Mexico
Prior art keywords
oxaliplatin
nanoparticles
prepared
active substance
mixed
Prior art date
Application number
MX2012003393A
Other languages
English (en)
Other versions
MX2012003393A (es
Inventor
Young Hoon Kim
Sung Jae Lee
Sang Heon Lee
Kab Sig Kim
Original Assignee
J W Pharmaceutical Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J W Pharmaceutical Corp * filed Critical J W Pharmaceutical Corp *
Publication of MX2012003393A publication Critical patent/MX2012003393A/es
Publication of MX348668B publication Critical patent/MX348668B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nanopartículas de oxaliplatin, que es una sustancia activa soluble en agua; a una composición farmacéutica que la contiene, y a un método para preparar nanopartículas de oxaliplatin administrables oralmente, emulsificando una solución de mezcla lípida en la que están mezclados un lípido sólido y un agente tensioactivo, en una solución de mezcla acuosa, en la que están mezclados el oxaliplatin y un cosolvente específico; y luego separar el lípido sólido y el cosolvente, usando un gas que es un fluido supercrítico. Al proveer el oxaliplatin, que actualmente sólo está disponible en forma de inyección para administración parenteral, en la forma de nanopartículas, la presente invención permite el desarrollo de oxaliplatin administrable oralmente, que es estable contra el ácido gástrico y tiene biodisponibilidad mejorada, mejorando de esa manera el cumplimiento del paciente al evitar la inconveniencia de la inyección y reduciendo en gran medida el costo médico. Puesto que se puede preparar las nanopartículas de oxaliplatin de manera económica usando una instalación que produzca fluido supercrítico, relativamente de bajo costo, puede prepararse mediante un proceso simple, con elevado rendimiento a escala comercial.
MX2012003393A 2009-09-21 2010-09-20 Nanopartículas de oxaliplatin y método para prepararlas. MX348668B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090089079 2009-09-21
PCT/KR2010/006459 WO2011034394A2 (ko) 2009-09-21 2010-09-20 옥살리플라틴의 나노 입자 및 이를 제조하는 방법

Publications (2)

Publication Number Publication Date
MX2012003393A MX2012003393A (es) 2012-07-25
MX348668B true MX348668B (es) 2017-06-23

Family

ID=43759199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003393A MX348668B (es) 2009-09-21 2010-09-20 Nanopartículas de oxaliplatin y método para prepararlas.

Country Status (11)

Country Link
US (1) US9393201B2 (es)
EP (1) EP2481396A4 (es)
JP (1) JP5759464B2 (es)
KR (1) KR101396461B1 (es)
CN (1) CN102665689B (es)
AU (1) AU2010296180B2 (es)
CA (1) CA2774669C (es)
IN (1) IN2012DN02576A (es)
MX (1) MX348668B (es)
RU (1) RU2563997C2 (es)
WO (1) WO2011034394A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188399A (zh) * 2013-03-15 2015-12-23 帝斯曼知识产权资产管理有限公司 固体脂质纳米颗粒（ii）
EP3613415B1 (en) * 2017-04-21 2022-11-09 Bio-Synectics Inc. Method for preparing active material nanoparticles using lipid as lubricant for milling
KR101895237B1 (ko) * 2017-06-12 2018-09-07 목포대학교산학협력단 옥살리플라틴을 포함하는 경구용 약물전달 조성물 및 이의 제조방법
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
WO2020053445A1 (en) 2018-09-14 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Drug delivery sytem for platinum-based drugs
CN110917345B (zh) * 2019-09-26 2021-11-09 苏州百迈生物医药有限公司 一种化疗免疫组合药物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
EA002630B1 (ru) * 1997-02-05 2002-08-29 Фармация Энд Апджон Компани Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US7012072B2 (en) 2000-12-12 2006-03-14 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CA2537170A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
CN1775216A (zh) * 2004-11-15 2006-05-24 胡才忠 一种新型的制剂——奥沙利铂脂质体
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
EA015781B1 (ru) * 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
KR20070067768A (ko) 2005-12-23 2007-06-29 주식회사 삼양사 안정한 옥살리플라틴 조성물 및 이의 제조방법
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
KR101342119B1 (ko) * 2006-05-04 2013-12-18 (주)바이오시네틱스 디올 화합물을 이용한 나노수준의 활성물질 입자 제조 방법
AU2007246277A1 (en) * 2006-05-04 2007-11-15 Bio-Synectics Inc. Method for preparing nano-scale particle of active material
CN1868455A (zh) * 2006-05-20 2006-11-29 沈阳药科大学 奥沙利铂磷脂复合物静脉给药的纳米混悬注射剂
KR100913063B1 (ko) 2006-09-13 2009-08-21 주식회사유한양행 옥살리플라틴-함유 주사용 용액
US20100021550A1 (en) * 2007-01-12 2010-01-28 Yanfang Li Radiopaque biodegradable vascular embolic microspheres
CN100563646C (zh) * 2007-07-13 2009-12-02 陈祥峰 一种奥沙利铂脂质体葡萄糖制剂的制备方法
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin

Also Published As

Publication number Publication date
AU2010296180B2 (en) 2016-05-05
CA2774669C (en) 2017-12-19
KR101396461B1 (ko) 2014-05-20
KR20120046243A (ko) 2012-05-09
MX2012003393A (es) 2012-07-25
US20120177728A1 (en) 2012-07-12
EP2481396A4 (en) 2014-03-05
JP2013505291A (ja) 2013-02-14
IN2012DN02576A (es) 2015-08-28
RU2563997C2 (ru) 2015-09-27
EP2481396A2 (en) 2012-08-01
RU2012116085A (ru) 2013-10-27
JP5759464B2 (ja) 2015-08-05
CN102665689A (zh) 2012-09-12
CN102665689B (zh) 2015-04-22
WO2011034394A2 (ko) 2011-03-24
AU2010296180A1 (en) 2012-04-19
US9393201B2 (en) 2016-07-19
WO2011034394A3 (ko) 2011-11-03
CA2774669A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
MX2012003393A (es) Nanoparticulas de oxaliplatin y metodo para prepararlas.
Gullapalli Soft gelatin capsules (softgels)
MX2011006771A (es) Metodo de preparacion de una composicion de micelas polimericas que contienen un farmaco pobremente soluble en agua.
CN103653179B (zh) 一种肉桂精油纳米脂质体及其制备方法
MX2011013726A (es) Nanodispersión de un medicamento y proceso para su preparación.
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
SG11201400144SA (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
PH12014500853A1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2013018050A3 (en) Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
BRPI0821739B8 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga
WO2011063774A3 (en) Pectin complexes of steroids and pharmaceutical compositions based thereon
WO2012145554A3 (en) Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof
WO2012145555A3 (en) Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
CN103027930B (zh) 一种可形成并缓释短分子多糖的生物质组合物、制备方法与制剂
WO2014045307A3 (en) Pharmaceutical composition
CN107865784A (zh) 一种基于协同美白作用的纳米级胶束爽肤水
WO2011162560A3 (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
CN105412002A (zh) 一种淫羊藿苷元口服制剂及其制备方法
TWI594760B (zh) 木棉花水萃物的用途
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
WO2013130785A3 (en) Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
Iswandana et al. Nanoparticles formulation from chitosan and sodium tripolyphosphate by ionic gelation method using verapamil hydrochloride as drug model

Legal Events

Date Code Title Description
FG Grant or registration